The Carnegie Capital Asset Management LLC decides to keep it stake in Walgreens Boots Alliance Inc. (WBA) to the level of $2,155,000

The Carnegie Capital Asset Management LLC decides to keep it stake in Walgreens Boots Alliance Inc. (WBA) to the level of $2,155,000

Carnegie Capital Asset Management LLC decreased its position in shares of Walgreens Boots Alliance Inc. (NASDAQ:WBA) by 1.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,799 shares of the pharmacy operator’s stock after selling 300 shares during the period. Carnegie Capital Asset Management LLC’s holdings in Walgreens Boots Alliance were worth $2,155,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Jolley Asset Management LLC boosted its position in shares of Walgreens Boots Alliance by 104.5% in the second quarter. Jolley Asset Management LLC now owns 1,370 shares of the pharmacy operator’s stock worth $114,000 after buying an additional 700 shares during the period. Cribstone Capital Management LLC purchased a new position in shares of Walgreens Boots Alliance during the second quarter worth approximately $149,000. MU Investments Co. Ltd. purchased a new position in shares of Walgreens Boots Alliance during the second quarter worth approximately $150,000. Signaturefd LLC boosted its position in shares of Walgreens Boots Alliance by 2.7% in the second quarter. Signaturefd LLC now owns 1,802 shares of the pharmacy operator’s stock worth $150,000 after buying an additional 48 shares during the period. Finally, Livingston Group Asset Management CO operating as Southport Capital Management purchased a new position in shares of Walgreens Boots Alliance during the second quarter worth approximately $188,000. Hedge funds and other institutional investors own 59.76% of the company’s stock.

Shares of Walgreens Boots Alliance Inc. (NASDAQ:WBA) traded down 1.29% during mid-day trading on Friday, hitting $81.10. The stock had a trading volume of 7,971,224 shares. The stock’s 50-day moving average price is $80.61 and its 200-day moving average price is $80.85. Walgreens Boots Alliance Inc. has a 12-month low of $71.50 and a 12-month high of $89.15. The stock has a market capitalization of $87.85 billion, a price-to-earnings ratio of 21.23 and a beta of 1.01.

Walgreens Boots Alliance (NASDAQ:WBA) last posted its quarterly earnings data on Thursday, October 20th. The pharmacy operator reported $1.07 EPS for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.08. Walgreens Boots Alliance had a net margin of 3.56% and a return on equity of 16.33%. The company earned $28.60 billion during the quarter, compared to the consensus estimate of $29.06 billion. During the same period in the prior year, the business posted $0.88 EPS. The company’s quarterly revenue was up .4% on a year-over-year basis. On average, equities analysts anticipate that Walgreens Boots Alliance Inc. will post $5.02 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 12th. Stockholders of record on Thursday, November 17th will be issued a $0.375 dividend. The ex-dividend date is Tuesday, November 15th. This represents a $1.50 dividend on an annualized basis and a dividend yield of 1.85%. Walgreens Boots Alliance’s payout ratio is 39.27%.

Several research analysts have commented on WBA shares. Evercore ISI reaffirmed a “buy” rating and set a $93.00 price target on shares of Walgreens Boots Alliance in a research report on Thursday, July 7th. FBR & Co cut their price target on Walgreens Boots Alliance from $90.00 to $85.00 and set a “market perform” rating on the stock in a research report on Thursday, July 7th. Jefferies Group reaffirmed a “neutral” rating on shares of Walgreens Boots Alliance in a research report on Thursday, July 7th. Barclays PLC lifted their price target on Walgreens Boots Alliance from $76.00 to $79.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 7th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Walgreens Boots Alliance in a research report on Thursday, July 7th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $91.35.

In other news, EVP Kathleen Wilson-Thompson sold 23,996 shares of the company’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $85.00, for a total value of $2,039,660.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 21.10% of the stock is currently owned by insiders.

Walgreens Boots Alliance Company Profile

Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).

Related posts

Leave a Comment